The formation of pathological thrombi in the circulatory system can produce significant unwanted consequences like embolism, ischemia, heart attack, stroke, etc. Currently available thrombolytic treatments using plasminogen activators are associated with high cerebral bleeding risks and a 2–3 h, narrow therapeutic time-window especially in case of ischemic stroke [1–4]. This evidence concerns the gene PLG and ischemic stroke.